Page last updated: 2024-12-10

methionyltryptophan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Met-Trp : A dipeptide formed from L-methionine and L-tryptophan residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3080870
CHEMBL ID3321992
CHEBI ID74709
SCHEMBL ID7048700
MeSH IDM0203619

Synonyms (19)

Synonym
methionyl-tryptophan
l-methionyl-l-tryptophan
met-trp
60535-02-6
l-tryptophan, n-l-methionyl-
chebi:74709 ,
chembl3321992 ,
bdbm50049749
methionyltryptophan
(2s)-2-[[(2s)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1h-indol-3-yl)propanoic acid
l-met-l-trp
n-l-methionyl-l-tryptophan
h-met-trp-oh
SCHEMBL7048700
DTXSID60209279
AKOS030525572
mfcd00037952
Q27144848
(2s)-2-[[(2s)-2-azaniumyl-4-methylsulfanylbutanoyl]amino]-3-(1h-indol-3-yl)propanoate

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Chromatographic, electrophoretic, and microscopic studies suggested that such decreases in absorption rate were caused mainly by decomposition of L-tryptophan to some basic incubation products containing tryptamine with consequent damage to the mucosal surface of everted sacs during long-term incubation."( Absorption rates of L-tryptophan, L-methionine, and L-methionyl-L-tryptophan by rat intestine in vitro and in vivo.
Ryu, K; Sakamoto, K; Yabe, Y,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1183271Inhibition of ACE (unknown origin)2014European journal of medicinal chemistry, Sep-12, Volume: 84CoMFA and CoMSIA analysis of ACE-inhibitory, antimicrobial and bitter-tasting peptides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.13 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]